AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05375383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic S. salivarius K12 lozenges containing prebiotic B
Description: In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
Study NCT05375383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic S. salivarius K12 lozenges containing prebiotics A and B
Description: In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
Study NCT04810221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled desaturation study
Description: Measure of SpO2 and Heart Rate by BrOxy M device and reference device in a controlled desaturation study.
Study NCT05375383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic S. salivarius K12 powder
Description: In this study, a powder will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
Study NCT05375383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic S. salivarius K12 powder containing prebiotic A
Description: In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
Study NCT05631093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART
Description: Standard of care ART, per approved product list, taken orally
Study NCT05631093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOR/ISL
Description: Combination of 100 mg doravirine (DOR) with 0.25 mg Islatravir (ISL) in tablet form, taken orally, once daily.
Study NCT05631093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOR/ISL
Description: Combination of 100 mg doravirine (DOR) with 0.25 mg Islatravir (ISL) in tablet form, taken orally, once daily.
Study NCT05027906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-1501
Description: Investigative Arm
Study NCT05375383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic S. salivarius K12 powder containing prebiotic B
Description: In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
Study NCT04806009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'Mindful Living With Insomnia (MLWI)' Intervention via WeChat mini-program
Description: The MLWI Intervention involves 12 sessions over 6 weeks course, 2 sessions a week and 0.5 hours per session. Two new sessions of online lessons will be updated weekly in the 6 weeks. Each session is consisted of theoretical lecture, mindfulness practices, sharing common difficulties and coping way during mindfulness practices and homework assignment in the form of video or audio. The Mindfulness practices embedded in the intervention include mindful breathing, mindful body scan, mindful dealing with thoughts and emotions, mindful meditation, mindful movement, and daily life mindfulness. In the intervention, the participants will also receive sleep hygiene education.Participants in the Intervention Group will receive the MLWI Intervention after follow the WeChat mini-program.
Study NCT04806009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 'Cognitive Behavioral Therapy for insomnia (CBT-I)'via WeChat mini-program
Description: The CBT-I involves 12 sessions over 6 weeks course, 2 sessions a week and 0.5 hours per session. Two new sessions of online lessons will be updated weekly in the 6 weeks. Each session is consisted of theoretical lecture, cognitive or behavioral regulation techniques, sharing common difficulties and coping way during mindfulness practices and homework assignment in the form of video or audio.Participants in the Control Group will receive CBT-I after follow the WeChat mini-program.
Study NCT04490720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: consume 1 sachet per day for 2 months
Study NCT04490720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Buckwheat husk extract
Description: consume 1 sachet per day for 2 months
Study NCT05438043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered either intravenously or subcutaneously.
Study NCT05438043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered intravenously.
Study NCT05438043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered either orally or intravenously.
Study NCT05438043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally.
Study NCT05438043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered orally.
Study NCT04963374 — intervention group
Intervention type: OTHER
Intervention: risk evolution scale
Description: Padua score、Caprini score、Prime score
Study NCT04582266 — intervention group
Intervention type: DRUG
Intervention: Remdesivir
Description: RDV was not provided as part of the study. Participants were administered RDV intravenously once daily for up to 10 days per clinical care.
Study NCT06177652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block
Description: Ultrasound (US) -guided paravertebral block (PVB) with 20 ml 0.5 % bupivacaine will performe preoperatively to all patients in the PVB group.
Study NCT06177652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Plane Block
Description: Ultrasound (US) -guided serratus plane block (SPB) with 20 ml 0.5 % bupivacaine will performe preoperatively to all patients in the SPB group.
Study NCT05426486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: HER2 antibody-drug conjugate
Study NCT05426486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib maleate
Description: EGFR/HER2 dual inhibitor
Study NCT05426486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: anti-Her2 monoclonal antibody
Study NCT05426486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: anti-HER2 monoclonal antibody
Study NCT05426486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Cytotoxic chemotherapy
Study NCT05426486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Cytotoxic chemotherapy
Study NCT06136598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opevesostat
Description: Tablets to be taken orally.
Study NCT06136598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets to be taken orally
Study NCT06136598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: Tablets to be taken orally.
Study NCT06136598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Tablet to be taken orally as a rescue medication.
Study NCT05375383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic S. salivarius K12 powder containing prebiotics A and B
Description: In this study, a powder containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
Study NCT05375383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic S. salivarius M18 lozenges
Description: In this study, a lozenge containing will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
Study NCT05375383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic S. salivarius M18 lozenges containing prebiotic A
Description: In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
Study NCT05375383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic S. salivarius M18 lozenges containing prebiotic B
Description: In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
Study NCT05375383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic S. salivarius M18 + lozenges containing prebiotic A and B
Description: In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
Study NCT06423859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine
Description: supraclavicular brachial plexus block with articaine 2%
Study NCT06423859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine
Description: supraclavicular brachial plexus block with articaine 2%
Study NCT06423859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: supraclavicular brachial plexus block with articaine 2% in addition with Dexmedetomidine
Study NCT05915832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
Study NCT05915832 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
Study NCT05875779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led vaccine education intervention
Description: The intervention will be delivered face-to-face by a trained peer-educator and will consist of one session of 10-20 minutes.~Peer vaccine educators will receive written vaccine materials for distribution. These materials will present content that accurately represents the risks and benefits of vaccination.~Responsibilities of the vaccine educators will be to: provide motivational interviewing with patients, provide vaccine counseling, address questions and concerns regarding available vaccines, brief clinical provider on hesitant patients and areas of their vaccine-related concerns, and provide follow-up with participants at day 30, day 60 and day 90 for additional engagement.
Study NCT05909878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The pre-procedural IVR game preparation (IMAGINE) was developed by Paperplane Therapeutics® (intervention development team). IMAGINE is an immersive virtual reality simulation aiming to reduce the anxiety and phobic reactions of young patients and to better prepare them for this exam. Since the game is a preparation, it is a no success game and is independent of the ability and previous experience of the child with video games. It offers an immersive and fun simulation that aims to desensitize young patients to MRI and transform an anxiety-inducing experience into a fun play session. The participant will learn about the main principles of magnetic resonance imaging and experience a very realistic simulation of the MRI exam. This will allow children to prepare for the MRI scanner by enabling them to experience the process of undergoing an MRI exam beforehand.
Study NCT05909878 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Protocol
Description: The usual care group will only receive the standard preparation, which comprises of an explanation of the MRI procedure given by the radiology technician as per the radiology department's protocol. Specifically at the hospital (HSJ), standard care also includes access to a television mounted near the MRI playing videos.The research nurse will be able to complete any information should they find it incomplete or substandard.
Study NCT05921305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX (5mg/m\^2/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR
Study NCT05921305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Corticosteroid Methylprednisolone 2 mg/kg/day was given for 3 days, and for responding patients, the dose of prednisone must be at least 0.25mg/kg/day prednisone (or 0.2mg/kg/day methylprednisolone).
Study NCT06569875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCARE
Description: iCARE is an internet-based cognitive behavioral therapy program designed for women experiencing symptoms of postpartum depression, including anxiety, irritability, and sadness. The program offers digital therapy through an online platform tailored to mothers with mild to moderate postpartum depression. The program consists of 7 modules, each with its own theme, incorporating cognitive behavioral therapy, a well-established therapeutic approach for depression. The content includes text, images, audio files, and short films, supplemented with small tasks to provide knowledge and tools to understand and manage one's situation. The treatment course is self-directed, allowing participants to engage with the content at their own pace and at times that are most convenient for them
Study NCT06343311 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: EB103
Description: EB103 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the EB103 transgene.
Study NCT06019689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMI
Description: Culturally Adapted manual-assisted problem solving training based Mobile Intervention (CAMI) for Suicidal Ideation. CMAP is a manual-assisted intervention which has been adapted from a self-help guide called Life After Self-Harm based on the principles of Cognitive behavioral therapy (CBT). This intervention is an evaluation of suicidal ideation, crisis skills, problem-solving and CBT techniques to manage emotions, negative thinking, interpersonal relationships and relapse prevention strategies.
Study NCT05503264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: In Part 1, study drug will be administered after all other study-related procedures have been performed at a site visit at Weeks 0, 2, 4, and every 4 weeks (Q4W) thereafter. Participants will receive satralizumab according to body weight. Study drug will be administered by subcutaneous (SC) injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit. In Part 2, participants will be asked to choose from one of the following options: Option 1: continue on randomized, double-blind study drug; Option 2: start open-label satralizumab based on body weight; Option 3: stop study treatment and continue follow-up assessments.
Study NCT05503264 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Satralizumab placebo prefilled syringe (PFS) is identical in composition to satralizumab PFS, but does not contain the satralizumab active ingredient and will be identical in appearance and packaging to satralizumab. A PFS (assembled with an needle safety device \[NSD\] and extended finger flange) filled with 0.5 milliliters (mL) of solution, corresponding to 60 milligrams (mg) satralizumab, may be used in Part 2 once it becomes available at the study site.
Study NCT04770064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose/short-duration Fisetin
Description: Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. It has senolytic properties that may provide therapeutic benefit for those with knee osteoarthritis. Participants will be asked to take approximately 20 mg/kg of body mass for 2 consecutive days, followed by a 28-day washout period, and then another 2-day administration.
Study NCT04770064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose/sustained-duration Fisetin
Description: Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. It has senolytic properties that may provide therapeutic benefit for those with knee osteoarthritis. Participants will be asked to take one, 100 mg capsule of fisetin daily for 90 days.
Study NCT04770064 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo capsule
Description: Participants will be asked to take one, 100 mg oral placebo capsule (corn starch) daily for 90 days.
Study NCT04999332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin, oxaliplatin, docetaxel, S-1
Description: Perioperative chemotherapy with LOTS
Study NCT06152185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: The mindfulness intervention includes 28 daily 20-minute audio lessons plus brief daily practice prompts. The first 14 lessons train techniques for developing foundational mindfulness skills through didactics and guided practice; the second 14 lessons review these techniques through guided practice. Based on the Unified Mindfulness system, lessons train 3 mindfulness skills: concentration, sensory clarity, and equanimity. Concentration, a state of stable attention, enables participants to monitor present-moment physical and emotional body experiences. Sensory clarity, the monitoring of momentary experiences, involves detecting subtle sensations and discriminating between different experiences. Equanimity, an attitude of acceptance toward momentary experiences, is trained through 3 strategies: (a) body relaxation, (b) mental welcoming, and (c) a gentle tone of voice. Practice prompts delivered 3 times daily encourage participants to practice brief moments of mindful awareness.
Study NCT06152185 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants in the EUC condition will have no study requirements during the 4-week intervention period, but they will receive a list of stress management resources upon randomization (websites, books, health tracking apps, and mental health services) with no additional intervention support.
Study NCT05939921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: T2DM patients will be provided with metformin in a specified dose
Study NCT06065020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIDACTIVA sessions
Description: Community health workers (CHWs) will delivered VIDACTIVA intervention that consists in 8 home-sessions, one hour duration, within a period of 14 weeks + 2 follow-up calls (monthly). In total, a period of 22 weeks.~The multicomponent intervention consist in the following:~Problem-Solving Exercises: These are basic structured exercises aimed at training older individuals in problem-solving. This activity is centered around the older adult, meaning the older adults guides this activity, and the CHWs is a facilitator.~Physical Activation: This component involves planning and scheduling enjoyable activities (physical or social) that the older adult chooses based on their preferences and capabilities.~Education on Depressive Symptoms (psychoeducation)
Study NCT06065020 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Study fieldworkers will provide 2 educational sessions (45-60 min) about mental health at old age and participant will be guided to mental health community services (primary care centers). One session after the enrolment (week 1) and one at the 14th week.
Study NCT06574698 — intervention group
Intervention type: DRUG
Intervention: Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy
Description: Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy
Study NCT05231772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces Boulardii Probiotic Supplement
Description: Probiotic yeast
Study NCT05231772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05088603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clear Mask
Description: The clear mask has a 4.75 x 1.35 inch clear window that allows for clear visibility of the mouth.
Study NCT05819008 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological Assessment
Description: To validate Mindmore Distance (MD), the following standard neuropsychological tests will be used in a testing session with a psychologist:~* Wordlist 1 and 2 from WMS-III (Wechsler, 1997). Equivalent to RAVLT in MD~* Coding from WAIS-IV (Wechsler, 2008). Equivalent to SDPT in MD~* Block Span from WMS-III (Wechsler, 1997). Equivalent to CBT in MD~* Trail Making Test from D-KEFS (Delis et al., 2001). Equivalent to TMT-Click in MD~* Color-Word Interference Test from D-KEFS. Equivalent to Stroop in MD~* Verbal fluency from D-KEFS. Equivalent to FAS in MD~All participants will complete some questionnaires: Hospital Anxiety and Depression Scale (Zigmond \& Snaith, 1983); Insomnia Severity Index (Bastien, Vallieres, \& Morin, 2001); Cognitive Failure Questionnaire (Broadbent, Cooper, FitzGerald, \& Parkes, 1982); Perceived Stress Scale (Levenstein et al., 1993); Multidimensional Fatigue Inventory (Smets, Garssen, Bonke, \& De Haes, 1995).